1. WHO, “Immunity passports” in the context of COVID-19, https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19 (accessed June 29, 2020).
2. Infectious Disease Society of America. IDSA COVID-19 antibody primer. August 18, 2020 https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/ (accessed August 31, 2020).
3. FDA coronavirus disease 2019 (COVID-19) EUA information for in vitro diagnostic products: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization (accessed August 31, 2020).
4. M.S. Tang, K.G. Hock, N.M. Logsdon et al., Performance of two SARS-CoV-2 serologic assays, Clin. Chem. June 18, 2020.
5. A. Bryan,G. Pepper,M.H. Wener et al., Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho, J. Clin. Microbiol. May 7, 2020.